Nedocromil
Alocril, Tilade (nedocromil) is a small molecule pharmaceutical. Nedocromil was first approved as Tilade on 1992-12-30. It is used to treat allergic conjunctivitis and pruritus in the USA.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| alocril | New Drug Application | 2018-07-17 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| allergic conjunctivitis | EFO_0007141 | D003233 | H10.44 |
| pruritus | HP_0000989 | D011537 | L29 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
R: Respiratory system drugs
— R01: Nasal preparations
— R01A: Decongestants and other nasal preparations for topical use
— R01AC: Antiallergic nasal preparations for topical use, excl. corticosteroids
— R01AC07: Nedocromil
— R03: Drugs for obstructive airway diseases
— R03B: Other drugs for obstructive airway diseases, inhalants in atc
— R03BC: Antiallergic inhalants for obstructive airway diseases, excl. corticosteroids
— R03BC03: Nedocromil
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01G: Decongestants and antiallergics
— S01GX: Other antiallergics in atc
— S01GX04: Nedocromil
HCPCS
No data
Clinical
Clinical Trials
93 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypertension | D006973 | EFO_0000537 | I10 | 2 | 4 | 15 | 30 | 12 | 61 |
| Heart failure | D006333 | EFO_0003144 | I50 | — | — | 1 | 3 | 2 | 6 |
| Prehypertension | D058246 | — | — | — | 3 | — | 3 | ||
| Coronary artery disease | D003324 | I25.1 | — | — | — | 2 | — | 2 | |
| Left ventricular dysfunction | D018487 | — | — | 1 | 1 | — | 2 | ||
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | — | 1 | — | 1 |
| Metabolic syndrome | D024821 | EFO_0000195 | E88.81 | — | — | — | 1 | — | 1 |
| Arterial pressure | D062186 | — | — | — | 1 | — | 1 | ||
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | — | — | — | 1 | — | 1 |
| Drug-related side effects and adverse reactions | D064420 | T88.7 | — | — | — | 1 | — | 1 |
Show 12 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Marfan syndrome | D008382 | Orphanet_558 | Q87.4 | — | — | 1 | — | — | 1 |
| Covid-19 | D000086382 | U07.1 | — | — | 1 | — | — | 1 | |
| Cardiomyopathies | D009202 | EFO_0000318 | I42 | — | — | 1 | — | — | 1 |
| Duchenne muscular dystrophy | D020388 | — | — | 1 | — | — | 1 | ||
| Peripheral arterial disease | D058729 | EFO_0004265 | — | — | 1 | — | — | 1 | |
| Pulmonary arterial hypertension | D000081029 | — | — | 1 | — | — | 1 | ||
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | — | 1 | — | — | 1 |
| Cardiotoxicity | D066126 | EFO_1001482 | — | — | 1 | — | — | 1 | |
| Large b-cell lymphoma diffuse | D016403 | C83.3 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Ischemic stroke | D000083242 | — | 1 | — | — | — | 1 | ||
| Essential hypertension | D000075222 | I10 | — | 1 | — | — | — | 1 | |
| Myocardial bridging | D054084 | — | 1 | — | — | — | 1 | ||
| Ocular hypertension | D009798 | EFO_1001069 | H40.0 | — | 1 | — | — | — | 1 |
| Open-angle glaucoma | D005902 | EFO_0004190 | H40.1 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 2 | — | — | — | — | 2 | ||
| Osteoporosis | D010024 | EFO_0003882 | M81.0 | 1 | — | — | — | — | 1 |
| Idiopathic pulmonary fibrosis | D054990 | J84.112 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | — | — | — | — | 1 | 1 |
| Exercise test | D005080 | EFO_0004328 | — | — | — | — | 1 | 1 | |
| Kidney transplantation | D016030 | — | — | — | — | 1 | 1 | ||
| Pure autonomic failure | D054970 | — | — | — | — | 1 | 1 | ||
| Multiple system atrophy | D019578 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | NEDOCROMIL |
| INN | nedocromil |
| Description | Nedocromil is a dicarboxylic acid and an organic heterotricyclic compound. It has a role as a non-steroidal anti-inflammatory drug, an anti-asthmatic drug and an anti-allergic agent. It is a conjugate acid of a nedocromil(2-). |
| Classification | Small molecule |
| Drug class | antiallergics (cromoglicic acid derivatives) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CCCc1c2oc(C(=O)O)cc(=O)c2cc2c(=O)cc(C(=O)O)n(CC)c12 |
Identifiers
| PDB | — |
| CAS-ID | 69049-73-6 |
| RxCUI | 31563 |
| ChEMBL ID | CHEMBL746 |
| ChEBI ID | 7492 |
| PubChem CID | 50294 |
| DrugBank | DB00716 |
| UNII ID | 0B535E0BN0 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,578 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
7,133 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more